Completed PHASE2 INTERVENTIONAL 2-arm NCT06193408

Assessment of a Novel Fixed-dose Combination (FDC) Drug VR-AD-1005 for the Treatment of Acute Watery Diarrhea in Cholera

Assessment of a Novel Fixed-dose Combination (FDC) Drug VR-AD-1005 for the Treatment of Acute Watery Diarrhea in Cholera: a Phase II, Randomized, Placebo-controlled, Double-blinded Efficacy and Safety Trial

Sponsor: Hunazine Biotech S.L.

Conditions Cholera

Interventions Placebo VR-AD-1005

Updated 6 times since 2024 Last updated: Feb 20, 2026 Started: Feb 11, 2024 Primary completion: Aug 11, 2024 Completion: Sep 8, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Cholera, this trial is completed. The trial is conducted by Hunazine Biotech S.L. and has accumulated 6 data snapshots since 2024. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Mar 2026 — Present [monthly]

Completed PHASE2
Oct 2024 — Mar 2026 [monthly]

Completed PHASE2

Status: Recruiting → Completed
Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Mar 2024 — Jul 2024 [monthly]

Recruiting PHASE2

▶ Show 1 earlier version

Feb 2024 — Mar 2024 [monthly]

Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hunazine Biotech S.L.

Data source: Hunazine Biotech S.L.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Dhaka, Bangladesh